Iron Metabolism Disorders Drugs Market: Industry Size, Share, Trends, Analysis Report and Forecast 2019 – 2027

138
business

Summary

Expanding Access to Treatment is Attributed to Growth of Global Iron Metabolism Disorder Drugs Market

Press Release

Placeholder Image

Global Iron Metabolism Disorder Drugs Market, by Indication (Anemia, Haemochromatosis), By Drug Types (Haemochromatosis –further segmented into Desferrioxamine mesilate, Diuretics, ACE Inhibitors; Anemia – further sub-segmented into Iron Supplements, Vitamin B supplements), By Distribution Channel (Hospital Pharmacy, Clinics, Retail Pharmacy, Drug Stores), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, & Africa) is expected to grow at a significant CAGR for the period between 2019 and 2027.

As per the report, increasing prevalence of anemia and haemochromatosis is attributed to growth of global iron metabolism disorder drugs market. As per World Health Organisation (WHO), anemia affects approximately 1.62 billion people across the globe. This constitutes 24.8% population of the world. The highest prevalence of anemia is found in preschool-age children. Highest number of individuals affected with anemia is non-pregnant women. Anemia is defined as a low level of hemoglobin in the blood, as evidenced by fewer numbers of functioning red blood cells. Haemochromatosis is a genetic disorder characterized by increased absorption of dietary iron from intestine. This excess iron accumulates in tissues and organs and interfere with their normal function. According to Haemochromatosis International organization, haemochromatosis is the most common genetic disorder. About 1 in 200 European people have the genetic risk for haemochromatosis. If undetected and untreated haemochromatosis can lead to premature death. Haemochromatosis is often undiagnosed because its symptoms are similar to those caused by a range of other illnesses. Under-diagnosis of haemochromatosis may present challenges to the growth of iron metabolism disorder drugs market. However, if haemochromatosis is detected before damage occurs, it can be easily treated.

Some of the key participating players identified in the study are Pfizer Inc., Novartis AG, Fresenius Kabi, Apopharma Inc., Gland Pharma Limited, Cipla, Abbott, Nestle, Pharmascience Inc., Bedford Pharmaceuticals etc. among others.